Ketamine a Panacea for Resistant Depression? Not So Fast, Experts Say Nancy A. Melville April 04, 2019 https://www.medscape.com/viewarticle/911378#vp_3 CHICAGO — Ketamine's rapid antidepressant effects and its recent approval by the US Food and Drug Administration (FDA) has clinicians and patients alike buzzing with excitement. However, for some experts, this excitement only serves to heighten concerns about the many unknowns and potential long-term side effects of the drug, which began its long history as an anesthetic. Here, at the Anxiety and Depression Association of American (ADAA) 2019 Conference, experts debated the drug's merits and potential pitfalls. "These are exciting times and I think ketamine has opened a new era," Carlos [...]
Lire la suiteDans la Silicon Valley, le retour des drogues psychédéliques Cinquante ans après le Summer of love, les ingénieurs et programmeurs de la Silicon Valley ont renoué avec les drogues psychédéliques, censées accroître la créativité et la performance. Les employeurs ferment les yeux, voire les encouragent. Par Elsa CONESA Publié le 04/04 à 06h00 https://www.lesechos.fr/tech-medias/hightech/dans-la-silicon-valley-le-retour-des-drogues-psychedeliques-1006461 Tous les matins, c'est le même rituel. « Je me lève, je bois un thé vert, je prends ma dose, puis je médite un peu. Sous la douche, déjà, je commence à sentir les bénéfices, j'ai plein d'idées qui apparaissent. » Lové dans un fauteuil de l'hôtel Rosewood Sand Hill, le QG officieux [...]
Lire la suiteAntidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. Rafael F. Sanchez, F. de Lima Osorio, R.G. Dos Santos, L.R. Macedo, J.P. Maia-de-Oliveira, L. Wichert-Ana, D.B. de Araujo, J. Riba, J.A. Crippa, J.E. Hallak Journal of Clinical Psychopharmacology, 2016, 36, 1, 77-81. doi: 10.1097/JCP.0000000000000436. PMID : 26650973 Abstract Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of [...]
Lire la suiteÉtat des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle Christian Sueur Psychotropes, 2017/3 (Vol. 23), p. 125-163. DOI 10.3917/psyt.233.0125 https://www.cairn.info/revue-psychotropes-2017-3-page-125.htm Résumé : L’utilisation thérapeutique des substances psychédéliques a été concomitante de la découverte du LSD et de la Mescaline après la Seconde Guerre mondiale. Ces utilisations thérapeutiques concernaient, à l’origine, essentiellement « l’accompagnement » des psychothérapies (thérapies psycholytiques), le traitement des addictions (alcool, puis opiacés) et, du fait de leurs capacités anxiolytiques et antidépressives, la prise en charge des troubles psychologiques post-traumatiques, les dépressions résistantes, les pathologies obsessionnelles et psychosomatiques (douleurs, migraines…) et l’accompagnement des fins [...]
Lire la suiteBIBLIOGRAPHIE : Ayahuasca Neurophysiologie, Pharmacologie, Thérapeutique et Chamanisme Dr Christian Sueur, GRECC, janvier 2020 22 pages 1 - Ayahuasca : généralités : 1 - 5 2 - Neurophysiologie de l’ayahuasca : 6 -8 3 - Pharmacologie de l’ayahuasca : 9 4 - Ayahuasca et Thérapeutique : 12 - 17 5 - Ayahuasca, spiritualité et Chamanisme :18 - 23
Lire la suiteRapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial ROSS S., BOSSIS A., GUSS J., AGIN-LIEBES G., MALONE T., COHEN B., MENNENGA S.E., BELSER A., KALLIONTZI K., BABB J., SU Z., CORBY P., SCHMIDT B.L. Journal of Psychopharmacology, 2016, 30, 12, 1165-1180 DOI: 10.1177/0269881116675512 jop.sagepub.com Abstract Background : Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods : In this double-blind, placebo-controlled, crossover trial, 29 patients [...]
Lire la suitePsilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer : A randomized double-blind trial GRIFFITHS R.R., JOHNSON M.W., CARDUCCI M.A., UMBRICHT A., RICHARDS W.A., RICHARDS B.D., COSIMANO M.P., KLINEDINST M.A. Journal of Psychopharmacology, 2016, 30, 12, 1181–1197. DOI: 10.1177/0269881116675513 jop.sagepub.com Abstract Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose [...]
Lire la suiteIncreased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression LYONS T., CARHART-HARRIS R.L. Journal of Psychopharmacology, 2018, 32, 7, 811-819. Doi : 10.1177/0269881117748902 journals.sagepub.com/home/jop Abstract Rationale : Previous research suggests that classical psychedelic compounds can induce lasting changes in personality traits, attitudes and beliefs in both healthy subjects and patient populations. Aim : Here we sought to investigate the effects of psilocybin on nature relatedness and libertarian authoritarian political perspective in patients with treatment-resistant depression (TRD). Methods : This open-label pilot study with a mixed-model design studied the effects of psilocybin on measures of nature relatedness and libertarian– authoritarian political perspective in patients with [...]
Lire la suiteEffects of psilocybin therapy on personnality structure ERRITZOE D., ROSEMAN L., NOUR M.M., MacLEAN K., KAELEN M., NUTT D.J., CARHART-HARRIS R.L. Acta Psychiatrica Scandinavica, 2018, 1-11. DOI : 10.1111/acps.12904 . Objective : To explore whether psilocybin with psychological support modulates personality parameters in patients suffering from treatment-resistant depression (TRD). Method : Twenty patients with moderate or severe, unipolar, TRD received oral psilocybin (10 and 25 mg, one week apart) in a supportive setting. Personality was assessed at baseline and at 3-month follow-up using the Revised NEO Personality Inventory (NEO-PI-R), the subjective psilocybin experience with Altered State of Consciousness (ASC) scale, and depressive symptoms with QIDS-SR16. Results : [...]
Lire la suiteQuality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Leor Roseman, David J. Nutt, Robin L. Carhart-Harris Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom Frontiers in Pharmacology, 2018, 8, article 974. Doi : 10.3389/fphar.2017.00974 . Introduction : It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) [...]
Lire la suite